TITLE

Tiotropium reduced exacerbations and health resource use in COPD

PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p64
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article discusses whether tiotropium is more effective than salmeterol or placebo in reducing exacerbations and health resource use in patients with chronic obstructive pulmonary disease (COPD). Patients who have received tiotropium had fewer COPD exacerbations and exacerbation-days per patient-year than patients who received placebo. In patients with chronic obstructive pulmonary disease, tiotropium reduced exacerbations, resource use and improved health-related quality of life more than placebo.
ACCESSION #
11533494

 

Related Articles

  • Tiotropium reduced exacerbations and health resource use in COPD: COMMENTARY. Mahler, Donald A. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p64 

    Researchers V. Brusasco and colleagues have focused on three outcomes exacerbations, health-related quality of life (HRQL) and dyspnea of the four important clinical outcomes in evaluating pharmacotherapy for chronic obstructive pulmonary disease (COPD). The requirement to stop inhaled...

  • Long acting β2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. Husereau, Don; Shukla, Vijay; Boucher, Michel; Mensinkai, Shaila; Dales, Robert // BMC Pulmonary Medicine;2004, Vol. 4, p1 

    Background: The long acting β2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with...

  • Add-on omalizumab improves QOL in severe allergic asthma.  // PharmacoEconomics & Outcomes News;12/16/2006, Issue 518, p9 

    The article reports on the improvement of quality of life (QOL) of patients with severe allergic asthma after taking add-on therapy with omalizumab according to a study. 2548 patients were used for the study. Using the Juniper Asthma QOL Questionnaire, patients who received omalizumab showed...

  • Antibiotics in chronic obstructive pulmonary disease. Hosker, Harold; Cooke, Nigel J.; Hawkey, Peter // BMJ: British Medical Journal (International Edition);4/2/94, Vol. 308 Issue 6933, p871 

    Investigates the effectiveness of antibiotics in treatment of patients with chronic obstructive pulmonary disease in Great Britain. Causes of exacerbations in patients; Association between Chlamydia pneumoniae, a respiratory pathogens and exacerbations of chronic pulmonary disease; Comparison...

  • Add inhaled corticosteroid for better COPD control.  // Pharmacy Today;Mar2007, Vol. 13 Issue 3, p2 

    The article reports on the findings of the study about the effectiveness of salmeterol-fluticasone propionate and salmeterol alone in preventing moderate and severe exacerbations of chronic obstructive pulmonary disease. The study, published in the January 15, 2007 issue of "American Journal of...

  • Budesonide/formoterol breathes QOL back into COPD patients.  // PharmacoEconomics & Outcomes News;1/31/2004, Issue 445, p14 

    Discusses research being done on the efficacy of budesonide and formoterol in a single inhaler on patients with chronic obstructive pulmonary disease. Reference to a study by P. M. Calverley et al published in the December 2003 issue of "European Respiratory Journal"; Improvement in lung...

  • Olodaterol/tiotropium improves QOL in patients with COPD.  // PharmacoEconomics & Outcomes News;Aug2015, Vol. 735 Issue 1, p24 

    The article reviews the report "Tiotropium+olodaterol Shows Clinically Meaningful Improvements in Quality of Life (QOL)," by D. Singh et al., published in the August 12, 2015 issue of "Respiratory Medicine," showing the drug improve QOL in patients with chronic obstructive pulmonary disease (COPD).

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY. Rees, P. John // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field...

  • Glycophosphopeptical benefit in COPD.  // PharmacoEconomics & Outcomes News;5/21/2005, Issue 478, p13 

    Discusses research being done on the effect of the treatment with the immunomodulator AM3 on the health-related quality of life of patients with chronic obstructive pulmonary disease. Reference to a study by L. J. Crofford et al, published in the April 2005 issue of the "Arthritis and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics